David R. Bauer
Lawyers
![](/sites/default/files/styles/teaser_headshot/public/lawyer-images/25898_drbauer.jpg?itok=Y1b0J_im)
Filters
Zoetis Inc. $1.5 Billion Senior Notes Offering
Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Zoetis Inc. of $300 million aggregate principal amount of its floating-rate senior notes…
REGENXBIO Inc. $175.5 Million Common Stock Offering
Davis Polk advised the representatives of the underwriters in connection with the $175.5 million offering of 2,700,000 shares of common stock of REGENXBIO Inc. The common stock is listed on…
BeiGene Ltd. HK$7.08 Billion (US$903 Million) Public Offering on the Hong Kong Stock Exchange
Davis Polk advised the underwriters and the joint global coordinators in the public offering of BeiGene, Ltd. on the Hong Kong Stock Exchange. The gross proceeds from the offering…
Davis Polk Advises AC Immune SA on Its $117.5 Million Follow-On Public Offering and Subscription Rights Offerings
Davis Polk advised AC Immune SA in connection with its $117.5 million U.S. follow-on public offering. AC Immune sold 8,500,000 of its newly issued common shares and subscription rights…
Constellation Pharmaceuticals Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with the $60 million initial public offering of common stock of Constellation Pharmaceuticals, Inc. The…
CytomX Therapeutics, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of CytomX Therapeutics, Inc. The shares are listed on the NASDAQ…
Davis Polk Advises Entera Bio Ltd. on Its Initial Public Offering
Davis Polk advised Entera Bio Ltd. on its initial public offering of 1,400,000 ordinary shares and 1,400,000 warrants to purchase up to 700,000 ordinary shares. In addition, Entera Bio Ltd…
Forty Seven, Inc. $112.6 Million Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 7,035,000 shares of common stock of Forty Seven, Inc. Forty Seven’s…
Magenta Therapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $100 million initial public offering of common stock of Magenta…
Aptinyx Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 7,359,998 shares of common stock of Aptinyx Inc., at $16.00 per share (which includes the exercise in…